Basal-cell carcinoma: No response versus relapse

The Lancet Oncology

Volumn 15, Issue 3, 2014, Pages

  Bassukas, Ioannis D ^a   Gaitanis, Georgios ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

BASAL CELL CARCINOMA; CANCER RECURRENCE; CRYOSURGERY; HUMAN; INTERMETHOD COMPARISON; LETTER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT FAILURE; TREATMENT RESPONSE;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; SKIN NEOPLASMS;

EID: 84894841693     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70014-2     Document Type: Letter

References (5)

1. Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 2014, 15:96-105. on behalf of the Surgery versus Imiquimod for Nodular and Superficial basal cell carcinoma (SINS) study group.
2. Gaitanis G, Bassukas ID Immunocryosurgery for non-superficial basal cell carcinoma: a prospective, open-label phase III study for tumours≤2 cm in diameter. Acta Derm Venereol 2014, 94:38-44.
3. van der Geer S, Martens J, van Roij J, et al. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. Br J Dermatol 2012, 167:110-115.
4. Gaitanis G, Bassukas ID Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma. J Eur Acad Dermatol Venereol 2013, published online Nov 29. 10.1111/jdv.12327.
5. Telfer NR, Colver GB, Morton CA Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008, 159:35-48.